Sanofi (SNY)
After hours:
| Previous close | 54.77 |
| Open | 54.91 |
| Bid | 54.90 x 200 |
| Ask | 54.96 x 500 |
| Day's range | 54.61 - 55.03 |
| 52-week range | 42.63 - 58.97 |
| Volume | |
| Avg. volume | 1,803,631 |
| Market cap | 137.981B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 29.87 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.04 (3.71%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
Press Release: Sanofi in discussions to sell a controlling stake in Opella
Sanofi in discussions to sell a controlling stake in Opella Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. Should these discussions lead to a positive outcome, any agreement would be subject to the completion of the necessary social processes. Further updates on the potential separation of Opella will be provided in due course, when a decision i
- GlobeNewswire
Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious Disease Society of America’s IDWeek 2024 annual meeting in Los Angeles, California, from October 16-19, 2024. Thomas TriompheExecutive Vice President, Vaccines, Sanofi “The data feat
- GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent approvals in the EU and China, the U.S. approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo Dupixent is the leading biologic medicine for al
